Ignite Creation Date:
2024-05-06 @ 6:08 PM
Last Modification Date:
2024-10-26 @ 2:43 PM
Study NCT ID:
NCT05569655
Status:
UNKNOWN
Last Update Posted:
2022-10-06
First Post:
2022-10-01
Brief Title:
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH
Sponsor:
Chinese Pulmonary Vascular Disease Research Group
Organization:
Chinese Pulmonary Vascular Disease Research Group
Study Overview
Official Title:
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With Right Heart Failure Caused by Pulmonary Arterial Hypertension
Status:
UNKNOWN
Status Verified Date:
2022-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Efficacy and safety evaluation of tolvaptan in the treatment of patients with right heart failure caused by pulmonary arterial hypertension
Detailed Description:
The study is a prospective single-center randomized controlled trial Specifically the research focuses on patients with right heart failure due to PAH in the Pulmonary Vascular Ward of Fuwai Hospital Within 12 hours of admission subjects were randomly assigned to two groups using the central randomization method The dose of tolvaptan 15 mgd is added to standard therapy including diuretics for subjects in group A Traditional standard therapy including diuretics is used for subjects in group B The treatment lasts for a total of seven days to assess the efficacy and safety of tolvaptan in the treatment of PAH-induced right heart failure An informed consent form must be signed by each participant in our study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None